Result of General Meeting
02 July 2010 - 9:16PM
UK Regulatory
TIDMIBL
RNS Number : 7368O
International Brand Licensing PLC
02 July 2010
+-+---------------------------------------------------------+----------+
| | International Brand Licensing plc ("IBL" or "the | |
| | Company") | |
+-+---------------------------------------------------------+----------+
Result of General Meeting
International Brand Licensing Plc (AIM: IBL), a growing business within the
in-vitro diagnostic devices market, is pleased to announce that at the General
Meeting held earlier today all resolutions were duly passed. The passing of the
resolutions will enable the Company to proceed with:
· The acquisition of EKF-diagnostic GmbH which is conditional, inter alia, on
Admission of the Placing Shares.
· The allotment of the Placing Shares, to raise gross proceeds of
approximately GBP15.06 million, the admission of which will take place in three
stages:
o In the First Admission, 10,666,665 new ordinary shares of 1p each will be
admitted to trading. The Company has made an application to the London Stock
Exchange and it is expected that First Admission will take place on 5 July 2010;
o In the Second Admission, a further 25,499,998 new ordinary shares of 1p each
will be admitted to trading. The Company has made an application to the London
Stock Exchange and it is expected that Second Admission will take place on 6
July 2010; and
o In the Third Admission, a further 64,268,990 new ordinary shares of 1p each
will be admitted to trading and all of the Existing Ordinary Shares will also be
readmitted to trading. The Company has made an application to the London Stock
Exchange and it is expected that Third Admission will take place on 7 July 2010.
· The Change of Name of the Company to EKF Diagnostics Holdings plc, which
will be effective (for the purposes of AIM) from 7 July 2010 (AIM trading symbol
will be EKF.L).
Definitions in this announcement are consistent with those set out in the
Admission Document issued to shareholders of the Company and dated 15 June 2010,
a copy of which is available on the Company's website.
Julian Baines, CEO of EKF Diagnostics Holdings plc commented: "The acquisition
of EKF-diagnostic GmbH is the first step in our strategy to build a diagnostics
business and gives us a good platform for future growth both organically and by
further acquisitions. We intend, in particular, to focus on devices and reagents
relating to diabetes, one of the fastest growing diseases in the world."
Enquiries:
+---------------------------------------+------------------------------+
| International Brand Licensing plc | |
+---------------------------------------+------------------------------+
| Julian Baines, CEO | Mob: 07788 420 859 |
+---------------------------------------+------------------------------+
| Paul Foulger, Finance Director | Tel: 020 7823 1733 |
+---------------------------------------+------------------------------+
| | |
+---------------------------------------+------------------------------+
| Zeus Capital (Nominated Adviser and | Tel: 0161 831 1512 |
| Joint Broker) | |
+---------------------------------------+------------------------------+
| Ross Andrews / Tom Rowley | |
+---------------------------------------+------------------------------+
| | |
+---------------------------------------+------------------------------+
| Matrix Corporate Capital LLP (Joint | Tel: 020 3206 7000 |
| Broker) | |
+---------------------------------------+------------------------------+
| Robert Naylor / Stephen Waterman | |
+---------------------------------------+------------------------------+
| | |
+---------------------------------------+------------------------------+
| Walbrook PR | Tel: 020 7933 8780 |
+---------------------------------------+------------------------------+
| Paul McManus / Ben Knowles | ben.knowles@walbrookpr.com |
+---------------------------------------+------------------------------+
Notes to editors
Details of acquisition and placing
In the announcement on 15 June 2010 IBL announced:
· an agreement to acquire EKF-diagnostic GmbH ("EKF") for a total
consideration of EUR14.32m to be satisfied by EUR11.32m in cash on completion and
EUR3m deferred consideration in shares; and
· a placing to raise approximately GBP15.06m (gross) by means of the issue of
100,435,653 new Ordinary Shares at 15 pence per share to fund the acquisition
and to provide working capital
About EKF Diagnostics Holdings plc
The acquisition of EKF-diagnostic GmbH ("EKF") has provided the Company with an
established, profitable and cash generative business within the diagnostic
devices industry. The Enlarged Group will be a manufacturer and distributor of
point of care diagnostic devices and reagents and will immediately have sales
and distribution channels into over 65 countries (including the key markets of
the US, Europe and Russia).
About EKF
EKF, based in Barleben, Germany, was founded in 1990 and focuses on the
development, manufacture and selling of diagnostic instruments and reagents to
clinical and research laboratories, doctors' offices and sports medicine testing
sites worldwide. EKF focuses on diabetes and anaemia testing, two of the main
segments of the point of care market.
This information is provided by RNS
The company news service from the London Stock Exchange
END
REGFLLFBBDFFBBF
International Brand Licensing (LSE:IBL)
Historical Stock Chart
From Dec 2024 to Jan 2025
International Brand Licensing (LSE:IBL)
Historical Stock Chart
From Jan 2024 to Jan 2025
Real-Time news about Intl.Brand (London Stock Exchange): 0 recent articles
More International Brand Licensing News Articles